共 113 条
[1]
Baser O(2011)Clinical and cost outcomes of venous thromboembolism in Medicare patients undergoing total hip replacement or total knee replacement surgery Curr Med Res Opin 27 423-429
[2]
Supina D(2002)Relative impact of risk factors for deep vein thrombosis and pulmonary embolism: a population-based study Arch Intern Med 162 1245-1248
[3]
Sengupta N(2012)Prevention of VTE in orthopedic surgery patients Chest 141 e278S-e325S
[4]
Heit JA(2012)In-hospital risk of venous thromboembolism and bleeding and associated costs for patients undergoing total hip or knee arthroplasty J Med Econ 19 768-776
[5]
O’Fallon WM(2014)Benefit-risk assessment of rivaroxaban versus enoxaparin for the prevention of venous thromboembolism after total hip or knee arthroplasty Vasc Health Risk Manag 137 3-10
[6]
Petterson TM(2005)Prevention of venous thromboembolism among hospitalized medical patients Circulation 6 59-74
[7]
Falck-Ytter Y(2011)Preventing venous thromboembolic disease in patients undergoing elective hip and knee arthroplasty Am Acad Orthop Surg 14 65-74
[8]
Francis CW(2016)The economic burden of incident venous thromboembolism in the United States: a review of estimated attributable healthcare costs Thromb Res 32 1063-1066
[9]
Johanson NA(2003)Economic burden of long-term complications of deep vein thrombosis after total hip replacement surgery in the United States Value Heal 25 789-798
[10]
Vekeman F(2011)Economic burden of venous thromboembolism: a systematic review J Med Econ 99 961-972